UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000004911 |
|---|---|
| Receipt number | R000005848 |
| Scientific Title | Phase I clinical trial of epitope peptides based vaccines targeting VEGFR1 in patients with advanced renal cell carcinoma |
| Date of disclosure of the study information | 2011/01/20 |
| Last modified on | 2013/07/24 11:24:39 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase I clinical trial of epitope peptides based vaccines targeting VEGFR1 in patients with advanced renal cell carcinoma
Acronym
Phase I clincal trial of epitope peptides based vaccines targeting VEGFR1 in patients with advanced renal cell carcinoma
Scientific Title
Phase I clinical trial of epitope peptides based vaccines targeting VEGFR1 in patients with advanced renal cell carcinoma
Scientific Title:Acronym
Phase I clincal trial of epitope peptides based vaccines targeting VEGFR1 in patients with advanced renal cell carcinoma
Region
| Japan |
Condition
Condition
advanced renal cell carcinoma
Classification by specialty
| Urology |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
safety
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Phase I
Assessment
Primary outcomes
Safety
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine | Vaccine |
Interventions/Control_1
Vaccination using epitope peptide
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
Performance status 0-2
HLA-A2 and/or -A24
No responce to (IL-2, IFN, sorafenib, sunitinib) etc
Key exclusion criteria
pregnancy
uncontroled infection
uncontroled cerebral metastasis
etc
Target sample size
18
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Uemura Hirotsugu |
Organization
Kinki University School of Medicine
Division name
Urology
Zip code
Address
377-2, Ohno-Higashi, Osaka-Sayama, Osaka, Japan
TEL
072-366-0221
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name |
Organization
Kinki University School of Medicine
Division name
Urology
Zip code
Address
TEL
Homepage URL
huemura@med.kindai.ac.jp
Sponsor or person
Institute
Department of Urology, Kinki University School of Medicine
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
近畿大学医学部付属病院 Kinki University School of Medicine Hostipal
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 01 | Month | 20 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2007 | Year | 05 | Month | 07 | Day |
Date of IRB
Anticipated trial start date
| 2007 | Year | 07 | Month | 01 | Day |
Last follow-up date
| 2012 | Year | 12 | Month | 01 | Day |
Date of closure to data entry
| 2012 | Year | 12 | Month | 31 | Day |
Date trial data considered complete
Date analysis concluded
| 2013 | Year | 04 | Month | 01 | Day |
Other
Other related information
K Yoshimura, T Minami, M Nozawa and H Uemura
Phase I clinical trial of human vascular
endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma
British Journal of Cancer (2013)
Management information
Registered date
| 2011 | Year | 01 | Month | 20 | Day |
Last modified on
| 2013 | Year | 07 | Month | 24 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005848
